Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
Materialtyp: Artigo
Språk:engelska
Publicerad: 2014
Länkar:https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Internet

https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf

Liknande verk